A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Sponsor: ImmusanT, Inc.
Listed as NCT03644069, this PHASE2 trial focuses on Autoimmune Diseases and Celiac and remains ongoing. Sponsored by ImmusanT, Inc., it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ImmusanT, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .